NASDAQ:BRNS Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis $0.98 0.00 (-0.01%) As of 03/10/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Barinthus Biotherapeutics Stock (NASDAQ:BRNS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BRNS alerts:Sign Up Key Stats Today's Range$0.95▼$1.0250-Day Range$0.93▼$1.2452-Week Range$0.80▼$4.16Volume23,248 shsAverage Volume38,199 shsMarket Capitalization$38.62 millionP/E RatioN/ADividend YieldN/APrice Target$5.17Consensus RatingBuy Company OverviewBarinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Read More… Remove Ads Barinthus Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreBRNS MarketRank™: Barinthus Biotherapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 704th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBarinthus Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBarinthus Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Barinthus Biotherapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Barinthus Biotherapeutics are expected to grow in the coming year, from ($1.38) to ($1.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Barinthus Biotherapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Barinthus Biotherapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBarinthus Biotherapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Barinthus Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the float of Barinthus Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBarinthus Biotherapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Barinthus Biotherapeutics has recently increased by 3.68%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBarinthus Biotherapeutics does not currently pay a dividend.Dividend GrowthBarinthus Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.04% of the float of Barinthus Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBarinthus Biotherapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Barinthus Biotherapeutics has recently increased by 3.68%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 2 people have searched for BRNS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Barinthus Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of Barinthus Biotherapeutics is held by insiders.Percentage Held by InstitutionsOnly 25.20% of the stock of Barinthus Biotherapeutics is held by institutions.Read more about Barinthus Biotherapeutics' insider trading history. Receive BRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Barinthus Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BRNS Stock News HeadlinesBarinthus price target lowered to $6 from $7.50 at Alliance Global PartnersFebruary 8, 2025 | markets.businessinsider.comBarinthus Biotherapeutics price target lowered to $3 from $5 at H.C. WainwrightJanuary 13, 2025 | markets.businessinsider.comA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.March 11, 2025 | Chaikin Analytics (Ad)Barinthus Biotherapeutics: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial UpdateJanuary 11, 2025 | finanznachrichten.deBarinthus announces strategic focus in I&I, provides financial updateJanuary 11, 2025 | markets.businessinsider.comBarinthus Bio's UK COO, CFO To Leave, Plans To Cut 65% Headcount To Expand Cash RunwayJanuary 10, 2025 | markets.businessinsider.comBarinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial UpdateJanuary 10, 2025 | globenewswire.comBarinthus Biotherapeutics Appoints New Chief Scientific OfficerNovember 27, 2024 | markets.businessinsider.comSee More Headlines BRNS Stock Analysis - Frequently Asked Questions How have BRNS shares performed this year? Barinthus Biotherapeutics' stock was trading at $1.2080 at the beginning of the year. Since then, BRNS shares have decreased by 20.5% and is now trading at $0.96. View the best growth stocks for 2025 here. How were Barinthus Biotherapeutics' earnings last quarter? Barinthus Biotherapeutics plc (NASDAQ:BRNS) released its earnings results on Wednesday, November, 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.23. The firm earned $14.97 million during the quarter. Who are Barinthus Biotherapeutics' major shareholders? Top institutional investors of Barinthus Biotherapeutics include Gilead Sciences Inc. (1.54%). How do I buy shares of Barinthus Biotherapeutics? Shares of BRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Barinthus Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Barinthus Biotherapeutics investors own include PayPal (PYPL), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Cogent Communications (CCOI), Datadog (DDOG), Intuitive Surgical (ISRG) and nCino (NCNO). Company Calendar Last Earnings11/06/2024Today3/10/2025Next Earnings (Estimated)3/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BRNS Previous SymbolNASDAQ:BRNS CIK1828185 Webwww.barinthusbio.com Phone44-1865-818-808FaxN/AEmployees107Year FoundedN/APrice Target and Rating Average Stock Price Target$5.17 High Stock Price Target$9.50 Low Stock Price Target$3.00 Potential Upside/Downside+424.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,350,000.00 Net MarginsN/A Pretax Margin-392.47% Return on Equity-34.26% Return on Assets-29.30% Debt Debt-to-Equity RatioN/A Current Ratio8.93 Quick Ratio8.93 Sales & Book Value Annual Sales$14.97 million Price / Sales2.65 Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book0.20Miscellaneous Outstanding Shares40,228,000Free Float37,010,000Market Cap$39.62 million OptionableN/A Beta-0.80 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:BRNS) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.